You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR ITACITINIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Itacitinib

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01626573 ↗	A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis	Completed	Incyte Corporation	Phase 2	This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
NCT01633372 ↗	An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis	Completed	Incyte Corporation	Phase 2	This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
NCT01634087 ↗	A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis	Completed	Incyte Corporation	Phase 2	This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.
NCT01858883 ↗	Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors	Completed	Incyte Corporation	Phase 1/Phase 2	Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Itacitinib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Solid Tumors	4
Myelofibrosis	4
B-Cell Malignancies	3
Non Small Cell Lung Cancer	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Graft vs Host Disease	15
Primary Myelofibrosis	7
Neoplasms	7
Carcinoma, Non-Small-Cell Lung	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Itacitinib

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	316
Japan	15
Canada	13
France	8
Spain	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	22
Texas	21
New York	19
Pennsylvania	17
Tennessee	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Itacitinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	26
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	19
Completed	9
Active, not recruiting	8
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Itacitinib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Incyte Corporation	40
National Cancer Institute (NCI)	6
M.D. Anderson Cancer Center	4
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	45
Other	27
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.